
    
      Patients will receive either ABVD chemotherapy (standard treatment = doxorubicin, bleomycin,
      vinblastine, dacarbazine) or the Brentuximab vedotin in combination with chemotherapy AVD
      (study treatment), depending on randomization. Radiotherapy is planned after chemotherapy or
      immunochemotherapy.

      PET scans will be performed before inclusion, after 2 cycles of chemotherapy and after 4
      cycles of chemotherapy (if PET after two cycles was positive), at the end of treatment and
      during follow-up period.
    
  